Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 6/20 | 0.60 |
| ▸ | CTSK | P43235 | 5/20 | 0.60 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.60 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.60 |
| ▸ | ACE | P12821 | 1/20 | 0.55 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.54 |
| ▸ | PPARA | Q07869 | 3/20 | 0.50 |
| ▸ | PPARG | P37231 | 2/20 | 0.48 |
| ▸ | CTSL | P07711 | 1/20 | 0.48 |
| ▸ | CTSB | P07858 | 1/20 | 0.48 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.48 |
| ▸ | BCL2 | P10415 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3270946 | 1.00 | CTSS (0.60) | CTSSCTSKITGB3ITGA2BACE | |
| SCHEMBL231980 | 0.90 | CTSS (0.71) | CTSSCTSKITGB3ITGA2BACE | |
| SCHEMBL1310547 | 0.90 | CTSS (0.71) | CTSSCTSKITGB3ITGA2BACE | |
| SCHEMBL231981 | 0.90 | CTSS (0.71) | CTSSCTSKITGB3ITGA2BACE | |
| Benzene SCHEMBL3925161 | 0.89 | CTSS (0.70) | CTSSCTSKITGB3ITGA2BACE | |
| Benzene SCHEMBL6474758 | 0.89 | CTSS (0.70) | CTSSCTSKITGB3ITGA2BACE | |
| SCHEMBL8669351 | 0.85 | ITGB3 (0.65) | CTSSCTSKITGB3ITGA2BACE | |
| SCHEMBL16993952 | 0.85 | ITGB3 (0.65) | CTSSCTSKITGB3ITGA2BACE | |
| SCHEMBL14343235 | 0.85 | ITGB3 (0.65) | CTSSCTSKITGB3ITGA2BACE | |
| SCHEMBL28630396 | 0.85 | CTSS (0.72) | CTSSCTSKITGB3ITGA2BACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0951295-B1 | COMPOSITIONS FOR USE IN INHIBITING OF ALPHA-V-BETA3 MEDIATED ANGIOGENESIS | SCRIPPS RESEARCH INST (US) | 2010-06-09 | — | — | EP | disclosed |
| US-20060270710-A1 | Methods for inhibition of angiogenesis | THE SCRIPPS RESEARCH INSTITUTE | 2006-11-30 | — | — | US | disclosed |
| US-20060165703-A1 | Methods and compositions useful for inhibition of alpha v beta 5 mediated angiogenesis | THE SCRIPPS RESEARCH INSTITUTE (US) | 2006-07-27 | — | — | US | disclosed |
| US-7053041-B1 | Methods and compositions useful for inhibition of αvβ5mediated angiogenesis | THE SCRIPPS RESEARCH INSTITUTE (US) | 2006-05-30 | — | — | US | disclosed |
| US-20040063790-A1 | Methods for inhibition of angiogenesis | THE SCRIPPS RESEARCH INSTITUTE | 2004-04-01 | — | — | US | disclosed |
| US-20030176334-A1 | Methods and compositions useful for inhibition of angiogenesis | THE SCRIPPS RESEARCH INSTITUTE (US) | 2003-09-18 | — | — | US | disclosed |
| US-6500924-B1 | PACKAGE FOR USING ANTAGONISTS OF THE VITRONECTIN RECEPTOR ALPHA-V BETA3 COMPRISING A METALLOPROTEINASE POLYPEPTIDE OF GIVEN AMINO ACID SEQUENCE; TREATING ARTHRITIS, RHEUMATOID ARTHRITIS, RETINOPATHY AND TUMORS | THE SCRIPPS RESEARCH INSTITUTE | 2002-12-31 | — | — | US | disclosed |
| EP-0907661-A4 | METHODS AND COMPOSITIONS USEFUL FOR INHIBITION OF alpha v beta 5 MEDIATED ANGIOGENESIS | SCRIPPS RESEARCH INST (US) | 2000-07-26 | — | — | EP | disclosed |
| EP-0907661-A1 | METHODS AND COMPOSITIONS USEFUL FOR INHIBITION OF alpha v beta 5 MEDIATED ANGIOGENESIS | The Scripps Research Institute (US) | 1999-04-14 | — | — | EP | disclosed |
| WO-1997045447-A9 | METHODS AND COMPOSITIONS USEFUL FOR INHIBITION OF αvβ5 MEDIATED ANGIOGENESIS | — | 1998-03-12 | — | — | WO | disclosed |
| WO-1997045447-A1 | METHODS AND COMPOSITIONS USEFUL FOR INHIBITION OF αvβ5 MEDIATED ANGIOGENESIS | THE SCRIPPS RESEARCH INSTITUTE (US) | 1997-12-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063790-A1 | Methods for inhibition of angiogenesis | FLT4, ANXA3, VCAM1 | CTSS 917/4885CTSK 1142/4885ITGB3 79/4885 |
| US-20030176334-A1 | Methods and compositions useful for inhibition of angiogenesis | VCAM1, FLT4, TEK | CTSS 1581/4885CTSK 1364/4885ITGB3 10/4885 |
| US-20060165703-A1 | Methods and compositions useful for inhibition of alpha v beta 5 mediated angiogenesis | ITGA5, ITGB5, ITGAV | CTSS 2377/4885CTSK 1771/4885ITGB3 11/4885 |
| US-20060270710-A1 | Methods for inhibition of angiogenesis | FLT4, KDR, FLT1 | CTSS 647/4885CTSK 709/4885ITGB3 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.